新辅助化疗、靶向治疗联合手术治疗临床Ⅲ期EGFR阳性肺腺癌  

Neoadjuvant chemotherapy,targeted therapy combined with surgery for clinical stageⅢlung adenocarcinoma with EGFR mutation

作　　者：赵晨[1] 张辉[1] 刘冬[1] 张淼[1] 武文斌[1] 周悦[2] Zhao Chen;Zhang Hui;Liu Dong;Zhang Miao;Wu Wenbin;Zhou Yue(Department of Thoracic Surgery,Xuzhou Central Hospital,Xuzhou 221009,China;Department of Cardiothoracic Surgery,The First Affiliated Hospital of NJMU,Nanjing 210029,China)

机构地区：[1]徐州市中心医院胸外科,徐州221009 [2]南京医科大学第一附属医院胸外科,南京210029

出　　处：《中华胸部外科电子杂志》2021年第1期16-20,共5页CHINESE JOURNAL OF THORACIC SURGERY：Electronic Edition

摘　　要：目的探讨临床Ⅲ(cⅢ)期且EGFR阳性的肺腺癌患者术前行新辅助化疗、靶向治疗后再手术这一新的综合治疗模式的安全性及有效性。方法选取2019年9月至2020年9月12例行新辅助治疗、靶向治疗cⅢ期EGFR阳性的肺腺癌患者为观察组,其中10例完成手术,作为A组;筛选同期单纯手术的20例cⅢ期患者为对照组(B组)。回顾性分析两组的病历资料。结果观察组中1例患者行新辅助化疗联合靶向治疗后出现疾病进展(PD),1例病灶稳定(SD)且PS 3分未进行手术,余10例患者肿瘤部分缓解(PR),均于化疗后3~4周接受手术治疗。术后病理证实辅助治疗降期效果明显(9/12)。A、B两组患者的性别、年龄、淋巴结清扫枚数、严重并发症发生率等差异均无统计学意义(P>0.05);A组术中平均出血量较B组多,术后住院时间延长,但差异无统计学意义(P>0.05);两组肿瘤分化程度差异有统计学意义(P<0.05)。结论经病理证实为cⅢ期肺腺癌,如EGFR阳性、健康状态较好(PS 0~2)的患者,术前行新辅助化疗、靶向治疗后再行外科手术可达到术前降期的效果,这一新的综合治疗模式安全且有效。Objective To investigate the safety and efficacy of neoadjuvant chemotherapy and targeted therapy combined with surgery in patients with clinical stageⅢ(cⅢ)lung adenocarcinoma with EGFR mutation.Methods Twelve patients with cⅢlung adenocarcinoma with EGFR mutation treated with neoadjuvant therapy and targeted therapy from September 2019 to September 2020 were selected,10 patients completed surgery was group A,and 20 patients with cⅢlung adenocarcinoma with EGFR mutation treated with surgery alone at the same period were selected as the control group(group B).The clinical data were retrospectively reviewed.Results Among the observation group,1 patient had disease progression(PD)after neoadjuvant chemotherapy combined with targeted therapy,1 patient had stable lesion(SD)and PS 3 score without surgery,and the remaining 10 patients with partial remission(PR)received surgery after chemotherapy 3–4 weeks.Postoperative pathology confirmed that the effect of adjuvant therapy was obvious(9/12).There was no significant difference in gender,age,number of lymph node dissection and incidence of serious complications between the two groups(P>0.05);the average intraoperative bleeding in group A was more than that in group B,and the postoperative hospital stay was longer,but there was no significant difference(P>0.05);there was significant difference in tumor differentiation between the two groups(P<0.05).Conclusion For patients with cⅢlung adenocarcinoma confirmed by pathology,and with EGFR positive with good health(PS 0–2),preoperative neoadjuvant chemotherapy and targeted therapy followed with surgery can reduce the preoperative clinical stage,and this new comprehensive treatment mode is safe and effective.

关 键 词：新辅助化疗 靶向治疗 肺腺癌 手术治疗 

分 类 号：R734.2[医药卫生—肿瘤]